

SolasCure's mission is to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients.

Chronic wounds are a growing global problem with imperfect solutions

- SolasCure Limited was born in 2017 as a spin-off from BRAIN AG, a leading German biotech company, with the goal of developing innovative, high-quality wound care products
- Chronic wounds are a massive problem in Europe and other parts of the world, with more than 40 million cases and a global market of \$10 billion
 - Demographic factors such as aging, rising obesity, diabetes and malnutrition are all causing this figure to rise
 - Such wounds need to be debrided - rid of dead tissue and dirt
 - Current solutions (surgery, autolytic debridement) have limitations
- Our first product, Aurase, is a hydrogel containing a safe, active, highly-specific enzyme, isolated and cloned from medical maggots
- In 2018, SolasCure raised a £2.6m Series A to continue development



(Click above to see an introductory video)

Aurase is an innovative gel-based product that efficiently & gently cleans wounds



- Semi-solid hydrogel formulation provides a moist wound environment and activates autolytic debridement
 - Utilizes the key mechanism of maggot debridement without the cost or labour input of live maggots
 - Facilitates and promotes the body's own wound cleansing processes
 - Reduces time to full debridement without delaying wound healing
- SolasCure is currently preparing a clinical study for Aurase in order to reach CE Mark as a Class III medical device

"The technology that **SolasCure** is developing has the potential to produce an effective, practical and easy to use new method of achieving an important goal in treating patients with wounds and **benefiting large numbers of patients.**"

- Prof. Keith Harding

SolasCure has assembled a world-class team



Dr. Sam Bakri
Executive Chairman

- Co-founded 3 MedTech cos.
- Advisor to UKTI & Helios
- Mayo Ventures & Johns Hopkins
- MBA - Harvard Business School



Prof. Keith Harding, CBE
Chair, Medical Advisory Board

- Director of Welsh Wound Innovation Center
- Head of Wound Healing Research in the School of Medicine at Cardiff



Benjamin Newmark
Chief Financial Officer

- Extensive startup leadership
- Former investment banker
- MBA & BA - Harvard



Prof. David Goldsmith
Chief Medical Officer

- Emeritus consultant kidney doctor at Guy's & St Thomas'
- Several academic positions
- Hirsch Index of 58



Dr. Bela Kelety
Chief Technology Officer

- Head of New Business Development at BRAIN
- Cofounded successful biotech company
- PhD from Max Planck Institute




Lily Bouzelmat
Director of Operations

- Led global Phase I to III clinical studies in various therapeutic areas
- Trained biologist

£10.6m capital to reach CE Mark

- August 2018 close: £2.6m (at £3.5m valuation)
- Tranched A2 raise of £8m to fund clinical programme



- Aim to have EIS eligibility after Tranche 1
- Grants & Tax Credits could reduce equity capital requirements

For additional information please contact sam@solascure.com or benjamin@solascure.com